Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma

Authors

Hiroyuki Kashiwagi, Washington University School of Medicine in St. Louis
Jonathan E. McDunn, Washington University School of Medicine in St. Louis
Peter O. Simon, Jr., Washington University School of Medicine in St. Louis
Peter S. Goedegebuure, Washington University School of Medicine in St. Louis
Suwanna Vangveravong, Washington University School of Medicine in St. Louis
Katherine Chang, Washington University School of Medicine in St. Louis
Richard S. Hotchkiss, Washington University School of Medicine in St. Louis
Robert H. Mach, Washington University School of Medicine in St. LouisFollow
William G. Hawkins, Washington University School of Medicine in St. Louis

Areas of Expertise

Richard S. Hotchkiss, 6520, Anesthesiology; William G. Hawkins, 7110, Surgery

Journal

Journal of Translational Medicine

Volume

26

Issue

7

Document Type

Article

Pages

24

Publication Date

2009

Recommended Citation

Kashiwagi, Hiroyuki; McDunn, Jonathan E.; Simon, Jr., Peter O.; Goedegebuure, Peter S.; Vangveravong, Suwanna; Chang, Katherine; Hotchkiss, Richard S.; Mach, Robert H.; and Hawkins, William G., "Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma". Journal of Translational Medicine, 24. 2009. Paper 77.
https://digitalcommons.wustl.edu/icts_facpubs/77